The Japan oncology drugs market size was accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2%

PORTLAND, OREGON, UNITED STATES, August 23, 2022 /EINPresswire.com/ -- Surge in prevalence of cancer is anticipated to significantly drive the growth of the Japan oncology drugs market. Furthermore, rise in geriatric population, increase in healthcare expenditure, and upsurge in awareness related to early screening of cancer are the key factors that augment the market growth.

The Japan oncology drugs market size was accounted for $9,405 million in 2018, and is expected to reach $14,109 million by 2026, registering a CAGR of 5.2% from 2019 to 2026.

For Right Perspective and Competitive Insights, Get Sample Report at: https://www.alliedmarketresearch.com/request-sample/5642

Cancerous cells are formed when the normal cells present in the body grow at an uncontrolled rate. This abnormal growth leads to the formation of a tumor which can spread to other localized tissues. Moreover, cancer has different stages based on the growth of tumor. Metastasis is the final stage of the disease, which is marked by the invasion of tumor in other parts of the body. The management of cancer in patients requires the use of different drugs such as hormonal therapy, immunotherapy, targeted therapy, and others.

Key Findings of the Japan Oncology Drugs Market :

Targeted therapy occupied approximately half share of the Japan oncology drugs market in 2018.

The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.

The gastrointestinal cancer segment accounted for two-fifth share of the market in 2018.

Lung cancer is anticipated to grow at the highest rate during the analysis period.

Comprehensive competitive analysis and profiles of major market players, such as

ABBVIE INC.
Astellas Pharma Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company, Limited
Hoffmann-La Roche AG
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Otsuka Holdings Co., Ltd.
Takeda Pharmaceutical Company Ltd.

Based on indication, the prostate cancer segment occupied the largest share of market in 2018 owing to the presence of huge geriatric population. However, lung cancer segment is expected to show fastest growth during the forecast period attributed to technological developments in the field of cancer diagnostics and rise in the awareness related to the early diagnosis of cancer.

According to Onkar Sumant, Manager, Healthcare at Allied Market Research, “Surge in prevalence of cancer is anticipated to significantly drive the growth of the Japan oncology drugs market. Furthermore, rise in geriatric population, increase in healthcare expenditure, and upsurge in awareness related to early screening of cancer are the key factors that augment the market growth.”

Table of Content:

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities…

Get upto 25% Discount: https://www.alliedmarketresearch.com/purchase-enquiry/5642

FREQUENTLY ASKED QUESTIONS?

Q1. What is the market value of Japan Oncology Drugs Market report in forecast period?
Q2. What would be forecast period in the market report?
Q3. What is the market value of Japan Oncology Drugs Market in 2020?
Q4. Which is base year calculated in the Japan Oncology Drugs Market report?
Q5. Does the Japan Oncology Drugs Market company is profiled in the report?
Q6. Which are the top companies hold the market share in Japan Oncology Drugs Market?
Q7. Does the Japan Oncology Drugs Market report provides Value Chain Analysis?
Q8. What are the key trends in the Japan Oncology Drugs Market report?

We also Offers Regional and Country Reports-

Japan Oncology Drugs Market
South Korea Oncology Drugs Market
Singapore Oncology Drugs Market
China Oncology Drugs Market
Indonesia Oncology Drugs Market
Australia Oncology Drugs Market
Taiwan Oncology Drugs Market

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.